Related Experiment Video
Updated: Oct 7, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
IFI30 as a prognostic biomarker and correlation with immune infiltrates in glioma
Wei Jiang1, Feifei Zheng2, Taotao Yao3
1Department of Neurology, the Second People's Hospital of Wuxi, Wuxi, China.
Background:
Increased evidence indicates that the tumour microenvironment (TME) plays an essential role in the development, treatment and prognosis of glioma. High expression of interferon-gamma-inducible protein 30 (IFI30) is associated with the malignant phenotype, but the effect of IFI30 on the tumour immune microenvironment and its potential role in the carcinogenesis of glioma remain unknown.
Methods:
The RNA sequencing (RNA-seq) data of 33 types of human cancer were obtained from The Cancer Genome Atlas (TCGA) Genomic Data Commons (GDC). R software was used to perform analyses, such as the expression of IFI30 in pan-cancer, evaluation of IFI30 as a prognostic biomarker in glioma, the relationship between IFI30 expression and clinical characteristics, and immune checkpoint. TIMER was used to analyse the correlation of IFI30 expression level with immune cell infiltration, and also to conduct survival analysis for immune cells and IFI30 in low grade glioma (LGG). DAVID was used for Gene Ontology (GO) functional annotations and Kyoto Encyclopedia of Genes and Genomes (KEGG) for pathway analysis of the genes similar to IFI30 in glioma. The differentially expressed genes (DEGs) between the high- and low-IFI30 expression groups were determined by DESeq2. Gene set enrichment analysis (GSEA) was then conducted to identify IFI30-related functional significance based on the hallmark gene set.
Results:
Dysregulated expression of IFI30 was associated with human cancers. High IFI30 expression was associated with poor overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI). Univariate and multivariate analyses identified IFI30 as an independent predictor for glioma. Meanwhile, IFI30 overexpression significantly correlated with high-grade tumours, poor OS, and immune infiltration. In addition, IFI30-associated genes significantly enriched the hallmark tumour progression-related clusters and cancer pathways.
Conclusions:
IFI30 is a prognostic biomarker correlated with immune infiltrates and acts as an oncogene in glioma.
Insights
Interferon-gamma-inducible protein 30 (IFI30) acts as an oncogene in glioma, correlating with poor survival and immune infiltration. High IFI30 expression indicates a poor prognosis and is linked to tumor progression, making it a potential therapeutic target.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- The tumor microenvironment (TME) is crucial in glioma development, treatment, and prognosis.
- High interferon-gamma-inducible protein 30 (IFI30) expression correlates with malignancy, but its role in glioma's immune microenvironment and carcinogenesis is unclear.
Purpose of the Study:
- To investigate the role of IFI30 in glioma.
- To evaluate IFI30 as a prognostic biomarker.
- To explore the association between IFI30 expression and the tumor immune microenvironment in glioma.
Main Methods:
- RNA sequencing data from The Cancer Genome Atlas (TCGA) for pan-cancer analysis.
- Analysis of IFI30 expression, prognostic value, and clinical correlations in glioma using R software.
- Immune cell infiltration analysis via TIMER.
- Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
- Differential gene expression analysis and Gene Set Enrichment Analysis (GSEA).
Main Results:
- IFI30 dysregulation is linked to various human cancers.
- High IFI30 expression is associated with poor overall survival, disease-specific survival, and progression-free interval.
- IFI30 is an independent predictor of glioma, correlating with high-grade tumors, poor survival, and immune infiltration.
- IFI30-associated genes are enriched in tumor progression pathways.
Conclusions:
- IFI30 serves as a prognostic biomarker in glioma.
- IFI30 expression correlates with immune infiltrates in glioma.
- IFI30 functions as an oncogene in glioma development and progression.
